Although their application in B-cell malignancies has not yet reached similarly satisfying results, preclinical experiments have highlighted the potential of targeting the BAFF/BAFF-R axis in CLL (41) and ALL (30). The gene discussed is TNFRSF13C; the disease is acute lymphoblastic leukemia.